Raymond Mason, MD
Family Medicine · Wooster, OHNPI 1609874403
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,044 of the $6,634 with a category attached, or 61.0%. Novartis accounts for 85.7% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $5,890 and has fallen 99.7% since, to $17 in 2025. Among family medicine clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 73 payments — averaging $90.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$6K
- Novo Nordisk$168
- AbbVie$165
- Boehringer Ingelheim$145
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$105
- Amarin Pharma, Inc.$76
- plus $289 from 10 others
Across 1 payment — averaging $4175.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sekisui Diagnostics LLC$4K
What the payments were for
- Consulting fees$4,04461%
- Travel & lodging$1,30420%
- Food & beverage$1,28519%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 11 | $5,686 |
| Novo Nordisk | 11 | $168 |
| AbbVie | 5 | $165 |
| Boehringer Ingelheim | 9 | $145 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $105 |
| Amarin Pharma, Inc. | 5 | $76 |
| AstraZeneca | 4 | $56 |
| GSK | 4 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $41 |
| Genentech USA, Inc. | 2 | $31 |
| Bayer | 2 | $26 |
| Johnson & Johnson | 2 | $23 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
| Merck | 1 | $13 |
| Almatica Pharma LLC | 1 | $11 |
How this compares
$6,634 in reported general payments places this provider in the 90th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 146 | $124,576 |
| MounjaroTirzepatide | 95 | $103,935 |
| OzempicSemaglutide | 64 | $100,483 |
| XareltoRivaroxaban | 84 | $78,305 |
| JardianceEmpagliflozin | 55 | $58,738 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $50,334 |
| JanuviaSitagliptin Phosphate | 22 | $33,568 |
| TrulicityDulaglutide | 16 | $22,274 |
| FarxigaDapagliflozin Propanediol | 29 | $20,674 |
| Breo ElliptaFluticasone/Vilanterol | 35 | $19,042 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 31 | $16,505 |
| Spiriva HandihalerTiotropium Bromide | 11 | $15,633 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 18 | $14,544 |
| SymbicortBudesonide/Formoterol Fumarate | 40 | $14,488 |
| LinzessLinaclotide | 22 | $11,665 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $17 | $126,209111 claims |
| Novo NordiskOzempic | $168 | $100,48364 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Combivent Respimat | $145 | $86,096106 claims |
| Johnson & JohnsonXarelto | $23 | $78,30584 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $51 | $71,89994 claims |
| MerckJanuvia, Janumet Xr | $13 | $48,11240 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $56 | $42,80482 claims |
| AbbVieLinzess | $165 | $11,66522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Wooster
- Kwabena OtengSpringdale$2M
- Brian BeesleyColumbus$1.4M
- Darshana PatelBeachwood$648K
- Thomas GraceFindlay$503K
- Susan RatayAshtabula$379K
- Shannon TrotterSpringfield$348K
- Michael HeileCincinnati$272K
- Bradley EverlyMaumee$266K
- Tricia BedrickCuyahoga Falls$259K
- David NeidhardtLima$248K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.